Xantina oxidasa (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Xantina oxidasa" in Spanish language version.

refsWebsite

Global rank Spanish rank

2^nd place

4^th place

1,293^rd place

471^st place

low place

7,029^th place

doi.org

Enroth C, Eger BT, Okamoto K, Nishino T, Nishino T, Pai EF (septiembre de 2000). «Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion». Proc. Natl. Acad. Sci. U.S.A. 97 (20): 10723-8. PMC 27090. PMID 11005854. doi:10.1073/pnas.97.20.10723.
Hille R. (2006). «Structure and Function of Xanthine Oxidoreductase». European Journal of Inorganic Chemistry 2006 (10): 1905-2095. doi:10.1002/ejic.200600087.
Dawson J, Walters M (octubre de 2006). «Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?». British Journal of Clinical Pharmacology 62: 633. PMC 1885190. PMID 17052251. doi:10.1111/j.1365-2125.2006.02785.x.
Pacher P, Nivorozhkin A, Szabó C (marzo de 2006). «Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of alopurinol». Pharmacol. Rev. 58 (1): 87-114. PMC 2233605. PMID 16507884. doi:10.1124/pr.58.1.6.
Spector T (enero de 1988). «Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical». Biochem. Pharmacol. 37 (2): 349-52. PMID 2829916. doi:10.1016/0006-2952(88)90739-3.
Muraoka S, Miura T (febrero de 2004). «Inhibition of xanthine oxidase by phytic acid and its antioxidative action». Life Sci. 74 (13): 1691-700. PMID 14738912. doi:10.1016/j.lfs.2003.09.040.

Mendoza Coussette, Ulises (2005). «Xantina oxidorreductasa, propiedades, funciones y regulación de su expresión genética». Instituto de Ciencias Básicas y Preclínicas “Victoria de Girón”. Rev Cubana Invest Biomed. Consultado el 24 de abril de 2017.

Enroth C, Eger BT, Okamoto K, Nishino T, Nishino T, Pai EF (septiembre de 2000). «Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion». Proc. Natl. Acad. Sci. U.S.A. 97 (20): 10723-8. PMC 27090. PMID 11005854. doi:10.1073/pnas.97.20.10723.
Dawson J, Walters M (octubre de 2006). «Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?». British Journal of Clinical Pharmacology 62: 633. PMC 1885190. PMID 17052251. doi:10.1111/j.1365-2125.2006.02785.x.
Pacher P, Nivorozhkin A, Szabó C (marzo de 2006). «Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of alopurinol». Pharmacol. Rev. 58 (1): 87-114. PMC 2233605. PMID 16507884. doi:10.1124/pr.58.1.6.
Spector T (enero de 1988). «Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical». Biochem. Pharmacol. 37 (2): 349-52. PMID 2829916. doi:10.1016/0006-2952(88)90739-3.
Muraoka S, Miura T (febrero de 2004). «Inhibition of xanthine oxidase by phytic acid and its antioxidative action». Life Sci. 74 (13): 1691-700. PMID 14738912. doi:10.1016/j.lfs.2003.09.040.